Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma.
Ontology highlight
ABSTRACT: Overall survival rates for patients with advanced osteosarcoma have remained static for over three decades. An in vitro analysis of osteosarcoma cell lines for sensitivity to an array of approved cancer therapies revealed that panobinostat, a broad spectrum histone deacetalyase (HDAC) inhibitor, is highly effective at triggering osteosarcoma cell death. Using in vivo models of orthotopic and metastatic osteosarcoma, here we report that panobinostat impairs the growth of primary osteosarcoma in bone and spontaneous metastasis to the lung, the most common site of metastasis for this disease. Further, pretreatment of mice with panobinostat prior to tail vein inoculation of osteosarcoma prevents the seeding and growth of lung metastases. Additionally, panobinostat impaired the growth of establ
SUBMITTER: McGuire JJ
PROVIDER: S-EPMC7787271 | biostudies-literature | 2020 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA